Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01222091 · ClinicalTrials.gov registry record · Phase 2

Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids

A Phase 2 study of Hyperalgesia, sponsored by Stanford University.

Completed
Registry status
Phase 2
Development phase
10
Enrollment target
1
Study location

NCT01222091 is a Phase 2 study of Hyperalgesia that has completed, run by Stanford University. The registered enrollment target is 10 participants, below the 214-participant average among 4 other Hyperalgesia trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01222091, a Phase 2 study of Hyperalgesia, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Phase 2
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This research study explores whether a beta-blocker (propranolol) can prevent a person from becoming more sensitive to pain after administration of an opioid (remifentanil). Beta blockers inhibit the sympathetic (fight or flight) response and are often used to treat angina and high blood pressure. In a previous study in human volunteers, the investigators demonstrated an increased sensitivity to pain after a 60-minute infusion of the opioid remifentanil. The goal of this study is to identify a possible inhibitor of this phenomenon.

Conditions Studied

Interventions

  • DRUG Propranolol
  • DRUG Remifentanil
  • DRUG Placebo to Match Propranolol

Study Locations (1)

California

  • Stanford University School of Medicine - Stanford

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2009-02
Est. Completion 2011-06
Phase Phase 2

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT01222091

The ClinicalTrials.gov registry entry for NCT01222091 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 214-participant average among 4 other Hyperalgesia trials with a reported enrollment target (95% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hyperalgesia appearing as the primary indexed condition, and to 3 interventions - of which Propranolol is the first listed.

NCT01222091 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01222091 about?

NCT01222091 is a clinical study titled "Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids". This research study explores whether a beta-blocker (propranolol) can prevent a person from becoming more sensitive to pain after administration of an opioid (remifentanil). Beta blockers inhibit the sympathetic (fight or flight) response and are often used to treat angina and high blood pressure. I...

What is the current status of trial NCT01222091?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2009-02. Estimated completion is 2011-06.

What conditions does trial NCT01222091 study?

This clinical trial studies the following conditions: Hyperalgesia.

What interventions are being tested in trial NCT01222091?

The interventions under investigation include: Propranolol (DRUG), Remifentanil (DRUG), Placebo to Match Propranolol (DRUG).

Who is sponsoring clinical trial NCT01222091?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01222091 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hyperalgesia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.